trending Market Intelligence /marketintelligence/en/news-insights/trending/iKywp9RxB-I-9X45D40XsQ2 content esgSubNav
In This List

Delcath Systems plans 1-for-100 reverse stock split

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Delcath Systems plans 1-for-100 reverse stock split

Delcath Systems Inc. said its board authorized a reverse stock split of the company's common stock at a ratio of 1-for-100.

The proposal for the stock split was approved by shareholders Sept. 17. The action will reduce the number of Delcath's issued and outstanding shares, as well as those reserved for issuance, to about 14 million from about 1.4 billion.

Starting Oct. 22, Delcath's shares will be designated by the symbol DCTHD for 20 trading days, after which the shares will be found under the DCTH symbol. The common stock will be assigned a new CUSIP number of 24661P 807 following the reverse stock split.

American Stock Transfer & Trust Co. is acting as the exchange agent and transfer agent for the reverse stock split.

New York-based Delcath Systems is a healthcare equipment company focusing on the treatment of primary and metastatic liver cancers. Its investigational products include melphalan hydrochloride for injection, which used to administer high-dose chemotherapy to the liver.